The literal 2026 U.S. top-10 cancer list includes non-Hodgkin lymphoma and leukemia. Because J'Onco Mentor already has a dedicated Hematopoietic Disorders module, this page focuses on 10 common anatomic solid cancer sites and includes pancreas and thyroid.
1
PROSTATE
Primary site: C61.9
5 MOST COMMON / HIGH-YIELD INVASIVE HISTOLOGIES
8140/3 — Adenocarcinoma, NOS / Acinar adenocarcinoma
8500/3 — Ductal adenocarcinoma
8574/3 — Adenocarcinoma with neuroendocrine differentiation
8041/3 — Small cell carcinoma
8070/3 — Squamous cell carcinoma
IN SITU / NONINVASIVE HISTOLOGIES
8010/2 — Carcinoma in situ, NOS (only when explicitly diagnosed)
High-grade prostatic intraepithelial neoplasia (PIN III) is not reportable.
2
BREAST
Primary site: C50._
5 MOST COMMON / HIGH-YIELD INVASIVE HISTOLOGIES
8500/3 — Invasive breast carcinoma of no special type / Ductal carcinoma, NOS
8520/3 — Invasive lobular carcinoma
8522/3 — Mixed ductal and lobular carcinoma
8480/3 — Mucinous carcinoma
8211/3 — Tubular carcinoma
IN SITU / NONINVASIVE HISTOLOGIES
8500/2 — Ductal carcinoma in situ (DCIS)
8520/2 — Lobular carcinoma in situ (LCIS)
8522/2 — Ductal and lobular carcinoma in situ
8503/2 — Intraductal / non-invasive papillary carcinoma
8504/2 — Encapsulated papillary carcinoma, non-invasive
Use the current Breast Solid Tumor Rules when multiple in-situ or invasive histologies are documented.
3
LUNG & BRONCHUS
Primary site: C34._
5 MOST COMMON / HIGH-YIELD INVASIVE HISTOLOGIES
8140/3 — Adenocarcinoma, NOS
8070/3 — Squamous cell carcinoma, NOS
8041/3 — Small cell carcinoma
8012/3 — Large cell carcinoma, NOS
8013/3 — Large cell neuroendocrine carcinoma
IN SITU / NONINVASIVE HISTOLOGIES
8070/2 — Squamous cell carcinoma in situ, NOS
8250/2 — Non-mucinous adenocarcinoma in situ
8253/2 — Mucinous adenocarcinoma in situ
8052/2 — Papillary squamous cell carcinoma, non-invasive
8010/2 — Carcinoma in situ, NOS
Moderate/severe squamous dysplasia of lung is not reportable.
4
COLON & RECTUM
Primary site: C18._–C20.9
5 MOST COMMON / HIGH-YIELD INVASIVE HISTOLOGIES
8140/3 — Adenocarcinoma, NOS
8480/3 — Mucinous adenocarcinoma
8490/3 — Signet ring cell adenocarcinoma
8560/3 — Adenosquamous carcinoma
8240/3 — Neuroendocrine tumor, NOS
IN SITU / NONINVASIVE HISTOLOGIES
8140/2 — Adenocarcinoma in situ
8480/2 — Low-grade appendiceal mucinous neoplasm (LAMN), when appendix applies
Colorectal dysplasia alone is not reportable in the U.S.; code carcinoma in situ only when explicitly diagnosed.
5
MELANOMA OF SKIN
Primary site: C44._
5 MOST COMMON / HIGH-YIELD INVASIVE HISTOLOGIES
8743/3 — Superficial spreading melanoma
8721/3 — Nodular melanoma
8744/3 — Acral lentiginous melanoma
8742/3 — Lentigo maligna melanoma
8720/3 — Malignant melanoma, NOS
IN SITU / NONINVASIVE HISTOLOGIES
8720/2 — Melanoma in situ, NOS
8742/2 — Lentigo maligna / Lentiginous melanoma in situ
Early/evolving melanoma in situ is reportable for cases diagnosed 2021 forward.
6
URINARY BLADDER
Primary site: C67._
5 MOST COMMON / HIGH-YIELD INVASIVE HISTOLOGIES
8120/3 — Urothelial carcinoma
8130/3 — Papillary urothelial carcinoma
8070/3 — Squamous cell carcinoma
8140/3 — Adenocarcinoma, NOS
8041/3 — Small cell carcinoma
IN SITU / NONINVASIVE HISTOLOGIES
8120/2 — Urothelial carcinoma in situ
8130/2 — Papillary urothelial carcinoma, non-invasive / in situ
Urothelial carcinoma is the dominant bladder histology.
7
KIDNEY / RENAL PELVIS
Primary site: C64.9 / C65.9
5 MOST COMMON / HIGH-YIELD INVASIVE HISTOLOGIES
8310/3 — Clear cell renal cell carcinoma
8312/3 — Renal cell carcinoma, NOS
8260/3 — Papillary renal cell carcinoma
8317/3 — Chromophobe renal cell carcinoma
8120/3 — Urothelial carcinoma of renal pelvis
IN SITU / NONINVASIVE HISTOLOGIES
8120/2 — Urothelial carcinoma in situ of renal pelvis
8130/2 — Papillary urothelial carcinoma, non-invasive / in situ of renal pelvis
In-situ urothelial codes apply to renal pelvis/urothelial sites, not typical renal parenchymal RCC.
8
CORPUS UTERI / ENDOMETRIUM
Primary site: C54._
5 MOST COMMON / HIGH-YIELD INVASIVE HISTOLOGIES
8380/3 — Endometrioid carcinoma
8460/3 — Serous carcinoma / Papillary serous carcinoma
8310/3 — Clear cell carcinoma
8950/3 — Carcinosarcoma / Malignant mixed Müllerian tumor
8890/3 — Leiomyosarcoma
IN SITU / NONINVASIVE HISTOLOGIES
No common routine in-situ histology listed for this site.
Endometrial hyperplasia with focal atypia is not reportable; do not assign /2 unless pathology explicitly establishes in-situ carcinoma.
9
PANCREAS
Primary site: C25._
5 MOST COMMON / HIGH-YIELD INVASIVE HISTOLOGIES
8500/3 — Ductal adenocarcinoma
8140/3 — Adenocarcinoma, NOS
8150/3 — Islet cell / pancreatic neuroendocrine carcinoma, NOS
8550/3 — Acinar cell carcinoma
8480/3 — Mucinous / colloid carcinoma
IN SITU / NONINVASIVE HISTOLOGIES
8148/2 — Pancreatic intraepithelial neoplasia, high grade (PanIN III)
8453/2 — Intraductal papillary mucinous neoplasm with high-grade dysplasia
8470/2 — Mucinous cystic neoplasm with high-grade dysplasia
8163/2 — Non-invasive pancreatobiliary neoplasia with high-grade dysplasia
PanIN low grade (formerly PanIN I/II) is not reportable; high-grade PanIN is reportable.
10
THYROID
Primary site: C73.9
5 MOST COMMON / HIGH-YIELD INVASIVE HISTOLOGIES
8260/3 — Papillary carcinoma
8330/3 — Follicular carcinoma
8290/3 — Oncocytic / Hürthle cell carcinoma
8345/3 — Medullary carcinoma
8021/3 — Anaplastic carcinoma
IN SITU / NONINVASIVE HISTOLOGIES
No common routine in-situ histology listed for this site.
No common routine thyroid in-situ histology is listed; use /2 only when pathology and current rules support it.